Phase 1 Trial with Soquelitinib, a Selective ITK Inhibitor for Treatment of Relapsed/Refractory T Cell Lymphomas
Richard A. Miller, Ning Ding, John Reneau, Yuqin Song et autres
0 citationsBlood
Suresh Mahabhashyam
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
10Publications signalées
121Citations signalées
1Affiliations récentes
Institutions déclarées
Domaines associés
Cancer Immunotherapy and BiomarkersLymphoma Diagnosis and TreatmentCAR-T cell therapy researchSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies
Publications récentes
Final results of a phase 1 trial with soquelitinib (SQL), a selective interleukin-2-inducible T cell kinase (ITK) inhibitor for treatment of relapsed/refractory (R/R) T cell lymphomas (TCL)
Richard A. Miller, Ryan A. Wilcox, John Reneau, Costas K. Yannakou et autres
2 citationsBlood
Anti-CD73 antibody activates human B cells, enhances humoral responses and induces redistribution of B cells in patients with cancer
Richard A. Miller, Jason J. Luke, Shenshen Hu, Suresh Mahabhashyam et autres
30 citationsJournal for ImmunoTherapy of Cancer
ITK Inhibitor Induces Dose-Dependent Th1 Skewing in Normal T Cells and Is Active in Refractory T Cell Lymphomas
Yuqin Song, Ning Ding, Dok Hyun Yoon, John Reneau et autres
4 citationsBlood
701 Activating CD73 on B cells as a target for immunotherapy of COVID-19 and viral associated cancers: clinical activity in human papilloma virus positive (HPV) head and neck squamous cell cancers (HNSCC)
Jason J. Luke, Jaime R. Merchan, Brett Hughes, Jeffrey A. Sosman et autres
3 citationsRegular and Young Investigator Award Abstracts
Clinical Results with a B Cell Activating Anti-CD73 Antibody for the Immunotherapy of COVID-19
Richard A. Miller, Pramod Guru, Philippe R. Bauer, Jorge Robles et autres
3 citationsmedRxiv
Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, Is Well-Tolerated and Active in Patients with T-Cell Lymphoma
Michael S. Khodadoust, Tatyana Feldman, Dok Hyun Yoon, Costas K. Yannakou et autres
13 citationsBlood
325 Immunotherapy with B cell activating antibody CPI-006 in patients (pts) with mild to moderate COVID-19 stimulates anti-SARS-CoV-2 antibody response, memory B cells and memory T effector cells
Gerard J. Criner, Mehrdad Mobasher, Craig Hill, Shenshen Hu et autres
1 citationRegular and Young Investigator Award Abstracts
Characterization and Phase 1 Trial of a B Cell Activating Anti-CD73 Antibody for the Immunotherapy of COVID-19
Stephen B. Willingham, Gerard J. Criner, Craig Hill, Shenshen Hu et autres
9 citationsmedRxiv
Initial results from first-in-human study of IPI-549, a tumor macrophage-targeting agent, combined with nivolumab in advanced solid tumors.
Ryan J. Sullivan, David S. Hong, Anthony W. Tolcher, Amita Patnaik et autres
56 citationsJournal of Clinical Oncology
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.